APA (7th ed.) Citation

Zhiwei Zheng, Jingrong Lin, Huide Zhu, & Hongfu Cai. (2022). Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Zhiwei Zheng, Jingrong Lin, Huide Zhu, and Hongfu Cai. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Zhiwei Zheng, et al. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Frontiers Media S.A., 2022.